Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Research-Driven Drug Makers Should Collaborate with Startups, Academia: MHLW Official
November 17, 2015
- PAFSC’s 2nd Committee to Review Lung Cancer Indication for Opdivo on Nov. 30
November 17, 2015
- PAFSC 1st Committee to Discuss Japan’s First PCSK9 Inhibitor on Nov. 27
November 16, 2015
- Novartis Japan Told to Improve Business over Delayed Reporting of Nearly 5,500 ADRs
November 16, 2015
- Business Improvement Order Issued to Novartis Japan
November 13, 2015
- “We Want to Avoid a Market Price Survey” Ahead of NHI Price Revision in FY2017: MHLW Official
November 13, 2015
- Re-Pricing of “Huge Seller” Drugs Seen Inevitable Despite Industry Opposition
November 12, 2015
- Chuikyo Leaning toward Continuing Innovation Premium for On-Patent Drugs
November 12, 2015
- Chuikyo Subcommittee Broadly OKs Price Maintenance Rule for Essential Drugs
November 12, 2015
- Financial Impact of New Drug Development Premium in FY2014 Revision Totaled 79 Billion Yen
November 12, 2015
- MHLW Floats Incentive for Hospital-Pharmacy Collaboration to Reduce Drugs Prescribed to Elderly
November 10, 2015
- JMA Reps Express Opposition to Expansion of Divided Dispensing of Long-Term Prescriptions at Chuikyo
November 10, 2015
- Novartis Fails to Report Nearly 5,500 Side Effect Cases, Biz Improvement Order Likely This Month
November 10, 2015
- MHLW Pitches Generic Incentive for In-Hospital Dispensing; Quality Worries Still Simmering at Chuikyo
November 9, 2015
- Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
- Generic Brand-Specified Prescriptions Not Permitting Substitution Decline to 15.9%: FY2015 Survey
November 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for October
November 6, 2015
- 4 PMDA Advisors to Resign over Conflicts of Interest
November 6, 2015
- AMED Now Taking Applications for Pre-Orphan Designation Scheme
November 6, 2015
- Chuikyo Payer Rep Urges Further Price Cuts for Long-Listed Products with Low Generic Rates
November 5, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…